Survey Shows Nurses Face Significant Burnout Risks in COVID-19 Pandemic
July 28, 2021 01:06pm
By Jill Murphy, Associate Editor
The FDA has approved marketing of Lupin Pharmaceuticalsâ€™ Lurasidone Hydrochloride Tablets
The FDA has approved marketing of Lupin Pharmaceuticals’ Lurasidone Hydrochloride Tablets, a generic version of Sunovion Pharmaceuticals, Inc's lurasidone HCl (Latuda) tablets, according to the company. Both products are approved for 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
According to Lupin's announcement, its Lurasidone Hydrochloride Tablets are indicated for treatment of adult patients with
, monotherapy treatment of adult patients with major depressive episode associated with bipolar I disorder, and adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder.
Lupin receives FDA approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg [news release]. Mumbai, India and Baltimore, MD; January 7, 2019: Lupin Pharmaceuticals website.
. Accessed January 7, 2019.